Please login to the form below
Brand teams: They're not what you think they are
Head of Commercial Matt Bolton of Blue Latitude Health breaks down what we mean when we talk about eliminating the last silos in pharma marketing.
Consultancies have been banging on about silos
and joined-up brand teams for years now, and many companies have taken heed
and started to work on breaking them down internally. Brands are developing
consolidated plans to deliver for their customers, not separating out
marketing, medical or market access activities.
However, this hasn't completely solved the problem. Pharma still has silos around key functions in the marketing process, which has the unintended consequence of often putting these functions at odds with the brand teams. This leads to a disjointed process and pulls the focus away from delivering value to customers. Don’t see your internal functions as a service to the brand, see them as a service to your customers.
In 2016, it’s time to bring these teams together and move them toward a common goal – delivering for your customers to enable better patient outcomes. Head of Commercial Matt Bolton breaks down what we mean when we talk about eliminating the last silos in pharma marketing.
![]()
However, this hasn't completely solved the problem. Pharma still has silos around key functions in the marketing process, which has the unintended consequence of often putting these functions at odds with the brand teams. This leads to a disjointed process and pulls the focus away from delivering value to customers. Don’t see your internal functions as a service to the brand, see them as a service to your customers.
In 2016, it’s time to bring these teams together and move them toward a common goal – delivering for your customers to enable better patient outcomes. Head of Commercial Matt Bolton breaks down what we mean when we talk about eliminating the last silos in pharma marketing.
Your partner in crime: Procurement
The role of procurement for professional services within pharmaceutical companies is growing. Currently though, its role is somewhat isolated from brand teams. They are often tasked with the difficult job of creating more efficiencies in the business while still enabling brand teams to work with agency partners to deliver for their customers. The issue becomes that unless your procurement colleagues have a deeper understanding of what brands’ customers need, they’re not making decisions about partners that reflect the best interests of the customers or the brand.Download the full article from Blue Latitude Health
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- The changing face of pharma in the precision era
- Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to prepare to bring precision medicines to market and how she is ensuring the patient is consulted every step of the way.
Blue Latitude Health
- Creative problem solving, solved
- Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.
Blue Latitude Health
- Three strategies for managing loss of exclusivity successfully
- Claire Taylor, Senior Associate Consultant at Blue Latitude Health explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
Blue Latitude Health
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Blue Latitude Health
- Diagnosing the lag in neuropsychiatric treatments
- The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health
